These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 18809819)

  • 1. Cost-effectiveness of HIV monitoring strategies in resource-limited settings: a southern African analysis.
    Bendavid E; Young SD; Katzenstein DA; Bayoumi AM; Sanders GD; Owens DK
    Arch Intern Med; 2008 Sep; 168(17):1910-8. PubMed ID: 18809819
    [TBL] [Abstract][Full Text] [Related]  

  • 2. When to initiate highly active antiretroviral therapy in sub-Saharan Africa? A South African cost-effectiveness study.
    Badri M; Cleary S; Maartens G; Pitt J; Bekker LG; Orrell C; Wood R
    Antivir Ther; 2006; 11(1):63-72. PubMed ID: 16518961
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Optimal frequency of CD4 cell count and HIV RNA monitoring prior to initiation of antiretroviral therapy in HIV-infected patients.
    Kimmel AD; Goldie SJ; Walensky RP; Losina E; Weinstein MC; Paltiel AD; Zhang H; Freedberg KA;
    Antivir Ther; 2005; 10(1):41-52. PubMed ID: 15751762
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost-effectiveness of laboratory monitoring for management of HIV treatment in sub-Saharan Africa: a model-based analysis.
    Hamers RL; Sawyer AW; Tuohy M; Stevens WS; Rinke de Wit TF; Hill AM;
    AIDS; 2012 Aug; 26(13):1663-72. PubMed ID: 22695297
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Monitoring of HIV viral load, CD4 cell count, and clinical assessment versus clinical monitoring alone for antiretroviral therapy in low-resource settings (Stratall ANRS 12110/ESTHER): a cost-effectiveness analysis.
    Boyer S; March L; Kouanfack C; Laborde-Balen G; Marino P; Aghokeng AF; Mpoudi-Ngole E; Koulla-Shiro S; Delaporte E; Carrieri MP; Spire B; Laurent C; Moatti JP;
    Lancet Infect Dis; 2013 Jul; 13(7):577-86. PubMed ID: 23602084
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical impact and cost-effectiveness of antiretroviral therapy in India: starting criteria and second-line therapy.
    Freedberg KA; Kumarasamy N; Losina E; Cecelia AJ; Scott CA; Divi N; Flanigan TP; Lu Z; Weinstein MC; Wang B; Ganesh AK; Bender MA; Mayer KH; Walensky RP
    AIDS; 2007 Jul; 21 Suppl 4(Suppl 4):S117-28. PubMed ID: 17620747
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Expanding antiretroviral options in resource-limited settings--a cost-effectiveness analysis.
    Bendavid E; Wood R; Katzenstein DA; Bayoumi AM; Owens DK
    J Acquir Immune Defic Syndr; 2009 Sep; 52(1):106-13. PubMed ID: 19448557
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Laboratory Monitoring of Antiretroviral Therapy for HIV Infection: Cost-Effectiveness and Budget Impact of Current and Novel Strategies.
    Ouattara EN; Robine M; Eholié SP; MacLean RL; Moh R; Losina E; Gabillard D; Paltiel AD; Danel C; Walensky RP; Anglaret X; Freedberg KA
    Clin Infect Dis; 2016 Jun; 62(11):1454-1462. PubMed ID: 26936666
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost-effectiveness of different strategies to monitor adults on antiretroviral treatment: a combined analysis of three mathematical models.
    Keebler D; Revill P; Braithwaite S; Phillips A; Blaser N; Borquez A; Cambiano V; Ciaranello A; Estill J; Gray R; Hill A; Keiser O; Kessler J; Menzies NA; Nucifora KA; Vizcaya LS; Walker S; Welte A; Easterbrook P; Doherty M; Hirnschall G; Hallett TB
    Lancet Glob Health; 2014 Jan; 2(1):e35-43. PubMed ID: 25104633
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost-effectiveness of screening for HIV in the era of highly active antiretroviral therapy.
    Sanders GD; Bayoumi AM; Sundaram V; Bilir SP; Neukermans CP; Rydzak CE; Douglass LR; Lazzeroni LC; Holodniy M; Owens DK
    N Engl J Med; 2005 Feb; 352(6):570-85. PubMed ID: 15703422
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Alternative antiretroviral monitoring strategies for HIV-infected patients in east Africa: opportunities to save more lives?
    Braithwaite RS; Nucifora KA; Yiannoutsos CT; Musick B; Kimaiyo S; Diero L; Bacon MC; Wools-Kaloustian K
    J Int AIDS Soc; 2011 Jul; 14():38. PubMed ID: 21801434
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost-effectiveness of HIV treatment in resource-poor settings--the case of Côte d'Ivoire.
    Goldie SJ; Yazdanpanah Y; Losina E; Weinstein MC; Anglaret X; Walensky RP; Hsu HE; Kimmel A; Holmes C; Kaplan JE; Freedberg KA
    N Engl J Med; 2006 Sep; 355(11):1141-53. PubMed ID: 16971720
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The cost-effectiveness of monitoring strategies for antiretroviral therapy of HIV infected patients in resource-limited settings: software tool.
    Estill J; Salazar-Vizcaya L; Blaser N; Egger M; Keiser O
    PLoS One; 2015; 10(3):e0119299. PubMed ID: 25793531
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The value of point-of-care CD4+ and laboratory viral load in tailoring antiretroviral therapy monitoring strategies to resource limitations.
    Hyle EP; Jani IV; Rosettie KL; Wood R; Osher B; Resch S; Pei PP; Maggiore P; Freedberg KA; Peter T; Parker RA; Walensky RP
    AIDS; 2017 Sep; 31(15):2135-2145. PubMed ID: 28906279
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Screening HIV-Infected Patients with Low CD4 Counts for Cryptococcal Antigenemia prior to Initiation of Antiretroviral Therapy: Cost Effectiveness of Alternative Screening Strategies in South Africa.
    Larson BA; Rockers PC; Bonawitz R; Sriruttan C; Glencross DK; Cassim N; Coetzee LM; Greene GS; Chiller TM; Vallabhaneni S; Long L; van Rensburg C; Govender NP
    PLoS One; 2016; 11(7):e0158986. PubMed ID: 27390864
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Projecting the cost-effectiveness of adherence interventions in persons with human immunodeficiency virus infection.
    Goldie SJ; Paltiel AD; Weinstein MC; Losina E; Seage GR; Kimmel AD; Walensky RP; Sax PE; Freedberg KA
    Am J Med; 2003 Dec; 115(8):632-41. PubMed ID: 14656616
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The cost effectiveness of antiretroviral treatment strategies in resource-limited settings.
    Bishai D; Colchero A; Durack DT
    AIDS; 2007 Jun; 21(10):1333-40. PubMed ID: 17545710
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The clinical and economic impact of point-of-care CD4 testing in mozambique and other resource-limited settings: a cost-effectiveness analysis.
    Hyle EP; Jani IV; Lehe J; Su AE; Wood R; Quevedo J; Losina E; Bassett IV; Pei PP; Paltiel AD; Resch S; Freedberg KA; Peter T; Walensky RP
    PLoS Med; 2014 Sep; 11(9):e1001725. PubMed ID: 25225800
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Early Treatment in HIV Patients: A Cost-Utility Analysis from the Italian Perspective.
    Marcellusi A; Viti R; Russo S; Andreoni M; Antinori A; Mennini FS
    Clin Drug Investig; 2016 May; 36(5):377-87. PubMed ID: 26940802
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effectiveness and cost effectiveness of early and late prevention of HIV/AIDS progression with antiretrovirals or antibiotics in Southern African adults.
    Bachmann MO
    AIDS Care; 2006 Feb; 18(2):109-20. PubMed ID: 16338768
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.